According to Zacks, “Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell’s most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy. In collaboration with Intrexon Corporation, a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. The Company’s lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma. “
Other research analysts have also recently issued research reports about the company. HC Wainwright reissued a “buy” rating and issued a $22.00 target price on shares of Fibrocell Science in a research note on Thursday, March 28th. ValuEngine raised Fibrocell Science from a “sell” rating to a “hold” rating in a research note on Tuesday, June 4th.
Fibrocell Science stock opened at $1.91 on Monday. The company has a market capitalization of $19.33 million, a PE ratio of -1.32 and a beta of 1.75. Fibrocell Science has a fifty-two week low of $1.45 and a fifty-two week high of $3.36. The stock has a fifty day moving average price of $1.97. The company has a current ratio of 3.59, a quick ratio of 3.59 and a debt-to-equity ratio of 0.85.
Fibrocell Science (NASDAQ:FCSC) last released its quarterly earnings results on Wednesday, May 15th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.07). As a group, equities research analysts forecast that Fibrocell Science will post -1.31 EPS for the current year.
A hedge fund recently raised its stake in Fibrocell Science stock. Virtu Financial LLC boosted its position in Fibrocell Science Inc (NASDAQ:FCSC) by 90.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 39,864 shares of the company’s stock after acquiring an additional 18,958 shares during the quarter. Virtu Financial LLC owned 0.41% of Fibrocell Science worth $77,000 as of its most recent filing with the Securities & Exchange Commission. 28.04% of the stock is owned by institutional investors.
About Fibrocell Science
Fibrocell Science, Inc, an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions.
See Also: What is a Reverse Stock Split?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with MarketBeat.com's FREE daily email newsletter.